Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$32.2 million.

  • C4 Therapeutics' Net Income towards Common Stockholders fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.51% up from last year.
  • As of Q3 2025, C4 Therapeutics' Net Income towards Common Stockholders stood at -$32.2 million, which was down 23.62% from -$26.0 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$15.7 million for Q4 2021, and its period low was -$35.9 million during Q2 2023.
  • For the 3-year period, C4 Therapeutics' Net Income towards Common Stockholders averaged around -$29.3 million, with its median value being -$28.4 million (2024).
  • As far as peak fluctuations go, C4 Therapeutics' Net Income towards Common Stockholders slumped by 75.07% in 2022, and later skyrocketed by 50.68% in 2024.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Net Income towards Common Stockholders stood at -$15.7 million in 2021, then slumped by 75.07% to -$27.4 million in 2022, then fell by 26.78% to -$34.8 million in 2023, then climbed by 0.52% to -$34.6 million in 2024, then crashed by 30.41% to -$32.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$32.2 million for Q3 2025, versus -$26.0 million for Q2 2025 and -$26.3 million for Q1 2025.